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Patient Characteristics of a Primary 
Care-Based Medication Assisted 
Treatment Program for Opioid Use 
Disorder in Philadelphia
Zoe Wong, Dr. Lara Weinstein*
Opioid Epidemic in the United States1
Opioid Epidemic in Philadelphia2
SOURCE: Philadelphia Department of Public Health, Opioid Misuse and Overdose Report 
(2020).
Medication Assisted Treatment (MAT)
Buprenorphine







• Opioid receptor 
antagonist
• Monthly injection





• Only administered at 
certified opioid 
treatment programs 
More effective in ↓ opioid use than non-medication treatment3
Disparities in MAT Access4-7
Decreased MAT Access







MAT in a Primary Care Setting
Low-Threshold Treatment Program8:
1) Same-day treatment entry
2) Harm-reduction approach
3) Flexibility
4) Availability in nontraditional settings (e.g. FQHC)
Goal: reduce disparities in treatment access for vulnerable populations
Project Hypothesis
Low-threshold model will increase marginalized 
population’s access to MAT.
Project Goals
Determine patient characteristics and compare 
results to city data.
Identify areas of program improvement and/or 
expansion based on patient characteristics.
Methods
Performance Accountability Reporting System (SPARS) Client 
Outcome Data
SAMHSA Center for Substance Abuse Treatment (CSAT) Government 
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Demographic Frequency (%) P-
value
PDPH 
Data2All (n=134) SKWC (n=83) Pathways (n=51)
Age Group (y) 18-24 1 (0.7) 1 (1.2) 0 (0.0) 0.749 3%
25-34 29 (21.6) 18 (21.7) 11 (21.6) 31%
35-44 38 (28.4) 20 (24.1) 18 (35.3) 32%
45-54 42 (31.3) 29 (34.9) 13 (25.5) 21%
55-64 21 (15.7) 13 (15.7) 8 (15.7) 11%
65 and older 3 (2.2) 2 (2.4) 1 (2.0) 2%
Gender M 82 (61.2) 49 (59.0) 33 (64.7) 0.745 61%
F 50 (37.3) 33 (39.8) 17 (33.3) 39%
Transgender 2 (1.5) 1 (1.2)0 (0.0)
Race White 66 (49.3) 28 (33.7) 38 (74.5) 0.675 50%
Black 61 (45.5) 49 (59.0) 12 (23.5) 0.373 28%
Other 7 (5.2) 6 (7.2) 1 (2.0)
SKWC: Stephen Klein Wellness Center
Pathways: Pathways to Housing PA 
PDPH: Philadelphia Department of Public Health
Results
Demographic Frequency (%) P-value
All (n=134) SKWC (n=83) Pathways (n=51)
Education Did not graduate 
high school 39 (29.1) 21 (25.3) 18 (35.3)
0.669
High school diploma 61 (45.5) 39 (47.0) 22 (43.1)
Some College 28 (20.9) 19 (22.9) 9 (17.6)
Bachelor's Degree or 
Higher 5 (3.7) 4 (4.8) 1 (2.0)
Unknown 1 (0.7) 1 (1.2) 0 (0.0)
Employment 
Status
Employed 28 (20.9) 21 (25.3) 7 (13.7) 0.275
Unemployed 101 (75.4) 59 (71.1) 42 (82.4)
Unknown 5 (3.7) 3 (3.6) 2 (3.9)
Housing Shelter 10 (7.5) 10 (12.0) 0 (0.0) 0.016*
Institution 4 (3.0) 2 (2.4) 2 (3.9)
Housed 120 (89.6) 71 (85.5) 49 (96.1)
SKWC: Stephen Klein Wellness Center
Pathways: Pathways to Housing PA 
PDPH: Philadelphia Department of Public Health
Results
Demographic Frequency (%) P-value
All (n=134) SKWC (n=83) Pathways (n=51)
Cocaine Use 0 days 85 (63.4) 60 (72.3) 25 (49.0) 0.042*
1-7 days 26 (19.4) 15 (18.1) 11 (21.6)
7-14 days 8 (6.0) 3 (3.6) 5 (9.8)
15 days or more 13 (9.7) 5 (6.0) 8 (15.7)
Marijuana Use 0 days 88 (65.7) 58 (69.9) 30 (58.8) 0.509
1-7 days 19 (14.2) 10 (12.0) 9 (17.
7-14 days 0 (0.0) 0 (0.0) 0 (0.0)
15 days or more 25 (18.7) 15 (18.1) 10 (19.6)
Alcohol Use 0 days 101 (75.4) 63 (75.9) 38 (74.5) 0.873
1-7 days 24 (17.9) 14 (16.9) 10 (19.6)
7-14 days 2 (1.5) 2 (2.4) 0 (0.0)
15 days or more 6 (4.5) 4 (4.8) 2 (3.9)
Results
Demographic Frequency (%) P-value
All (n=134) SKWC (n=83) Pathways (n=51)
Depressed 0 days 36 (26.9) 25 (30.1) 11 (21.6) 0.672
1-7 days 30 (22.4) 19 (22.9) 11 (21.6)
7-14 days 21 (15.7) 12 (14.5) 9 (17.6)
15 days or more 47 (35.1) 27 (32.5) 20 (39.2)
Anxious 0 days 24 (17.9) 16 (19.3) 8 (15.7) 0.618
1-7 days 26 (19.4) 17 (20.5) 9 (17.6)
7-14 days 24 (17.9) 12 (14.5) 12 (23.5)
15 days or more 60 (44.8) 38 (45.8) 22 (43.1)
History of violence or 
trauma Yes 112 (83.6) 70 (84.3) 42 (82.4)
0.517
Effects of violence or 
trauma 
Nightmares 88 (78.6) 57 (81.4) 31 (73.8) 0.487
On Constant 
Guard 87 (77.7) 56 (80.0) 31 (73.8)
0.567
Feels Numb or 
Detached 72 (64.3) 47 (67.1) 25 (59.5)
0.545
Conclusions
Program engaged a larger % of Black patients and 
patients over 54 than Philadelphia MAT programs 
citywide.
Program serviced a high % of patients who are 
unemployed and have a lower education level.
Program increases MAT 
access to marginalized 
populations.
Patients at Pathways to Housing PA location have 
a higher incidence of cocaine use. 
Increased cocaine abuse counseling and 
treatment may benefit patients at this 
location.
83.6% of patients have a history of violence or 
trauma, with a majority experiencing regular 
effects from that violence/trauma
Increasing trauma counseling and 
improving trauma-informed care will likely 
benefit program participants.
A majority of patients experience regular 
feelings of depression (50.8%) and anxiety 
(62.7%). 
Increased screening and treatment for 
depression and anxiety-related disorders 
will likely benefit program participants.
Limitations & Future Directions
o Assess changes in characteristics of MAT program 
over time
o Determine if any of the characteristics explored 
affect MAT retention rate 
Limitation to project expansion: 
inadequate 3/6-month follow up data 
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